Skip to main content

AI Bias Analysis

4 models · Takes ~15 seconds

MedPage Today

Novel Agent Reduces Seizures in Treatment-Resistant Epilepsy

Novel Agent Reduces Seizures in Treatment-Resistant Epilepsy
ShareXFacebook

(MedPage Today) -- Investigational azetukalner met its primary endpoint of reducing focal onset seizure frequency across two doses, initial findings from the phase III X-TOLE2 trial showed. Over 12 weeks, adjunctive treatment with 25 mg azetukalner...

M

Source

MedPage Today

Read full article at MedPage Today

Opens original article in a new tab

Advertisement

Related Health Stories

What's Next for Biologics in Atopic Dermatitis?
MedPage Today

What's Next for Biologics in Atopic Dermatitis?

(MedPage Today) -- During the recent American Academy of Dermatology (AAD) annual meeting, MedPage Today brought together three expert leaders for a virtual roundtable discussion on atopic dermatitis: Moderator Peter A. Lio, MD, of Northwestern...

Read more →
Advertisement